Our study aimed to assess the usefulness of aiMAT on non-IgE-sensitized or myeloma IgE-sensitized LAD2 cells (NS-LAD2 or S-LAD2, respectively) to evaluate aiMAT as a diagnostic tool in CSU and to differentiate its subtypes based on the response to omalizumab treatment. This evidence concerns the gene IGHE and plasma cell myeloma.